Skip to NavigationSkip to content

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

Published on 20/05/19 at 01:13pm

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours have epidermal growth factor receptor (EGFR) amplification, after it was identified in an interim analysis that the therapy presented no survival benefit to patients.

The disappointing news comes after an Independent Data Monitoring Committee (IDMC) discovered that the drug, when combined with the standard regimen of radiation and temozolomide, lacked survival benefit compared to placebo, and thus recommended that the trial be stopped.

"Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers," explained Dr Michael Severino, Vice Chairman and President at AbbVie.

The company also announced that enrolment has been placed on hold for all ongoing studies involving Depatux-M.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches